Document Detail

Survival of infiltrative hepatocellular carcinoma patients with preserved hepatic function after treatment with transarterial chemoembolization.
MedLine Citation:
PMID:  23283527     Owner:  NLM     Status:  Publisher    
PURPOSE: Transarterial chemoembolization (TACE) is highly effective and safe therapeutic modality for unresectable hepatocellular carcinoma (HCC). However, the role of TACE for infiltrative HCC has never been elucidated owing to the concern about hepatic failure and subsequent mortality after the procedure. In this study, we aimed to document whether patients with infiltrative HCC would benefit from TACE. METHODS: Child-Pugh class A/B patients who were newly diagnosed as infiltrative HCC and treated with curative-intent TACE were enrolled. All radiological images were reviewed by a radiologist with more than 20 years of experience in TACE. RESULTS: Among 1,184 patients newly diagnosed as HCC, 233 (19.7 %) had infiltrative-type tumors and 128 (54.9 %) underwent curative-intent TACE. Although the median overall survival was 5.4 months (IQR 3.1-13.9 months) and 16 (12.5 %) patients had experienced significant complications, 19 (15.9 %) patients survived more than 2 years after the first diagnosis. In multivariable analysis, age >60 years old (HR 0.54, 95 % CI 0.31-0.92), Child-Pugh class A (HR 0.48, 95 % CI 0.30-0.76), and a major PVT without parasitic supply (HR 0.66, 95 % CI 0.44-0.99) were independent favorable prognostic factors. Development of significant complication after TACE was a significant hazard factor of survival (HR 1.99, 95 % CI 1.09-3.62). CONCLUSIONS: In carefully selected patients with preserved hepatic function and good performance, TACE may achieve long-term survival of infiltrative HCC patients with major PVT without parasitic supply. However, the risk of morbidity and immediate mortality after TACE should be considered to select subjects for the procedure.
Eun Sun Jang; Jung-Hwan Yoon; Jin Wook Chung; Eun Ju Cho; Su Jong Yu; Jeong-Hoon Lee; Yoon Jun Kim; Hyo-Suk Lee; Chung Yong Kim
Related Documents :
17377387 - Clinical epidemiology of invasive cutaneous malignant melanoma in the austrian province...
1951177 - Phase ii trial of cimetidine in metastatic melanoma. a hoosier oncology group trial.
20070457 - Late recurrence (10 years or more) of malignant melanoma in south-east germany (saxony)...
8025897 - Melanoma in a southeastern hispanic population.
49217 - Current concepts of chemotherapy combined with other modalities for head and neck cancer.
19931907 - Response to recombinant erythropoietin alpha, without the adjunct of granulocyte-colony...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-1-3
Journal Detail:
Title:  Journal of cancer research and clinical oncology     Volume:  -     ISSN:  1432-1335     ISO Abbreviation:  J. Cancer Res. Clin. Oncol.     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-1-3     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7902060     Medline TA:  J Cancer Res Clin Oncol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnamsi, Gyeonggido, Republic of Korea.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A randomized and open-label trial evaluating the addition of pazopanib to lapatinib as first-line th...
Next Document:  Predictors of early distant metastasis in women with breast cancer.